Proteon Therapeutics to Present at Two Upcoming Investor Conferences

WALTHAM, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases, today announced that Company management will present at the following upcoming investor conferences: 

• Cowen and Company 38th Annual Health Care Conference in Boston, MA on Monday, March 12, 2018 at 12:00 pm ET; and 
• Oppenheimer 28th Annual Healthcare Conference in New York, NY on Wednesday, March 21, 2018 at 3:55 pm ET.

About Proteon Therapeutics

Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon has completed enrollment in PATENCY-2, a Phase 3 clinical trial evaluating vonapanitase in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis. Proteon is also evaluating vonapanitase in a Phase 1 clinical trial in patients with peripheral artery disease (PAD). For more information, please visit www.proteontx.com.

Investor ContactGeorge Eldridge, Proteon Therapeutics, Senior Vice President and Chief Financial Officer781-890-0102[email protected] 

Media ContactAnn Stanesa, Ten Bridge Communications617-230-0347[email protected]  

You May Also Be Interested In

• Sui Price Prediction: Can SUI Hit $5 as Next Crypto To Explode AlphaPepe Builds Four Products Pre-Launch?
• The Games DEA Attorneys Play: What Marijuana Rescheduling Closing Brief Didn't Tell Judge Julius
• NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.